#United States #New York #Pomerantz LLP #Investor Alert #Outset Medical

Pomerantz Law Firm Investigates Outset Medical, Inc.

On November 20, 2025, Pomerantz LLP announced an investigation into potential securities fraud involving Outset Medical, Inc. (NASDAQ: OM). This inquiry aims to determine if the company, along with specific officers and directors, engaged in unethical business practices that could harm investors. Investors are encouraged to reach out to Danielle Peyton at [email protected] or via phone at 646-581-9980, ext. 7980, for more information.

Background of Outset Medical

Outset Medical is a prominent developer of innovative medical technologies focused on transforming dialysis treatment. Despite its significant contributions to healthcare, the company has faced scrutiny regarding its operational and financial transparency.

Recent Financial Performance

The investigation follows Outset Medical’s disappointing financial report for the third quarter of 2025, released on November 10, 2025. The report disclosed a non-GAAP earnings per share of -$0.69, which fell short of the consensus estimate by $0.03. Furthermore, a reported revenue of $29.43 million did not meet expectations by $1.27 million.

Data reveal that the company lowered its revenue outlook for the year, projecting a range between $115 million and $120 million, a decrease from the previous estimate of $122 million to $126 million. This revision was justified by altered anticipations regarding the timing of large business opportunities expected in the latter half of 2025.

Market Reaction

Following this announcement, Outset Medical’s stock price plummeted by $5.85 per share, representing a massive 48.47% decrease, and closing at $6.22 per share on November 11, 2025. Such a significant drop signals investor concern over the company's future and raises questions about its operational integrity.

Role of Pomerantz LLP

Founded by Abraham L. Pomerantz, a pioneer in the class action field, Pomerantz LLP has earned a reputation for effectively representing victims of securities fraud and corporate misconduct. The firm has successfully recouped extensive damages for class members, reinforcing its commitment to protecting shareholders' rights.

Pomerantz’s involvement underscores the seriousness of the allegations and their commitment to uncovering the truth behind Outset Medical’s financial disclosures. Investors who may have been affected are urged to consider their legal options and engage with the firm’s team to understand their rights and possible recourse.

Conclusion

As the investigation unfolds, the focus will be on the actions of Outset Medical’s management team concerning investor communications and the accuracy of their reported financial results. The firm’s track record in handling securities class actions offers a pathway for shareholders seeking justice and clarity amidst growing uncertainty regarding Outset Medical’s business operations and performance.

Investors are advised to remain informed about developments and explore their potential involvement in any actions that arise as a result of this inquiry. For further engagement, those interested can follow up with Pomerantz LLP for updates on this significant case.

For more details about the case and to discuss potential claims, visit the Pomerantz LLP website or contact their office directly.